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Background
OnabotulinumtoxinA (Botox®) is the first and so far the
only treatment to receive a specific license for preven-
tion of chronic migraine (CM). In our Headache Clinic
the therapy with onabotulinumtoxinA is routinely admi-
nistered to CM patients on a daily basis since 2001.
Preventive treatment with onabotulinumtoxinA was
offered to all patients that were 1) adults; 2) fulfilling
the ICHD-II criteria for CM with or without analgesic
overuse; and 3) with contraindications or lack of efficacy
or tolerability to other preventive drugs.
Exclusion criteria were coexistent of neuromuscular
disorders, psychiatric diseases considered incompatible
with such kind of treatment, pregnancy and breast-
feeding.
Objectives
To prospectively evaluate the variations in terms of head-
ache days, migraine days, acute pain medication intake
days through a period of 24 months in comparison to a
one-month baseline period before starting the therapy.
Methods
Among all the patients that from 2011 to 2012 under-
went treatment with onabotulinumtoxinA we randomly
selected 100 CM patients (F 85 / M 15; mean age 45.4,
range 18-75 years; 93% drugs overusers) that were able
to fill diaries without any lack of information for a per-
iod of 2 years. OnabotulinumtoxinA 195 U was injected
in 39 sites combining the PREEMPT “fixed sites/fixed
doses” and the “follow the pain” injection paradigm
every three months (± one week)[1]. Patients with cri-
teria for medication overuse headache underwent with-
drawal and detoxification therapeutic regimen before
starting the treatment. Patients were not allowed to con-
tinue preventive oral medication during treatment with
onabotulinumtoxinA.
Results
The efficacy results for each timeline are reported in
Table 1. The reduction in terms of headache and
migraine days, acute medication intake days and HIT-6
score increases strongly from the first injection to the
fourth, and remains stable until the last injection at
24 months.
Conclusions
Our results support the findings of the PREEMPT study
in a large cohort of patients and are representative of
the patients observed in a tertiary headache centre.
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Table 1 Efficacy of onabotulinumtoxinA 195 U.
baseline 3 m 6 m 9 m 12 m 15 m 18 m 21 m 24 m
Headache days 22.2 -8.1 -12 -14.7 -16.5 -16.8 -17.2 -17.7 -18.1
Migraine days 21.6 -7.3 -10.4 -13.1 -15.9 -16.7 -17 -17.5 -17.6
Acute pain medication intake days 21 -7.1 -11.1 -13.8 -15.7 -16 -16.2 -17 -17.3
HIT-6 score 67.9 – -7 – -11.1 – -13.9 – -19
Negro et al. The Journal of Headache and Pain 2015, 16(Suppl 1):A177
http://www.thejournalofheadacheandpain.com/content/16/S1/A177
© 2015 Negro et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Written informed consent to publish was obtained
from the patient(s).
Published: 28 September 2015
Reference
1. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ:
Method of injection of onabotulinumtoxinA for chronic migraine: a safe,
well-tolerated, and effective treatment paradigm based on the PREEMPT
clinical program. Headache 2010, 50(9):1406-1418.
doi:10.1186/1129-2377-16-S1-A177
Cite this article as: Negro et al.: O068. A 2 years prospective evaluation
study on onabotulinumtoxinA 195 U in chronic migraine. The Journal of
Headache and Pain 2015 16(Suppl 1):A177.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Negro et al. The Journal of Headache and Pain 2015, 16(Suppl 1):A177
http://www.thejournalofheadacheandpain.com/content/16/S1/A177
Page 2 of 2
